20:27 , Jul 3, 2019 |  BC Extra  |  Company News

July 3 Company Quick Takes: Dovato approved in Europe for HIV; plus Alexion, RedHill and Insys

EC approves Dovato for HIV The European Commission approved once-daily Dovato dolutegravir/lamivudine from ViiV Healthcare Ltd. (Brentford, U.K.) to treat HIV-1 infection in adults and adolescents above 12 years of age. Third approval for Ultomiris...
01:58 , Jun 29, 2019 |  BioCentury  |  Finance

Biotech backs down in 2Q19

In a reversal from 1Q19, biotech stocks across all market cap tiers fell in the second quarter, leading to a total loss of $22.3 billion. However, the year-to-date change in market cap remains well in...
00:47 , Jun 29, 2019 |  BioCentury  |  Finance

All eyes on new modality launches, cancer and rare disease data in 3Q19

While the typical summer lull means fewer catalysts in the third quarter, investors will be keeping a close eye on launches of new modality drugs. Of special interest to multiple buysiders is the launch of...
01:12 , Jun 28, 2019 |  BC Extra  |  Company News

June 27 Company Quick Takes: Zogenix soars; plus Gardasil, Darzalex, Soliris and more

Zogenix shares surge after agreement to resubmit Fintepla NDA  Zogenix Inc. (NASDAQ:ZGNX) closed up $8.24 (21%) to $47.65 on Thursday after the company announced it had reached an agreement with FDA to resubmit its NDA...
23:32 , Jun 24, 2019 |  BC Extra  |  Company News

Management Tracks: Kress to succeed Moroney at MorphoSys; plus Sutro, Entasis and more

MorphoSys AG (Xetra:MOR; NASDAQ:MOR) said Jean-Paul Kress will take over as CEO from Simon Moroney, who in February announced his decision not to renew his contract as a member of MorphoSys’ management board, on Sept....
00:24 , Jun 21, 2019 |  BC Extra  |  Company News

June 20 Company Quick Takes: Priority Review for Alexion, Melinta therapies; plus Alimera, Denovo and more

Priority Review for Alexion's Ultomiris sBLA  FDA accepted and granted Priority Review to an sBLA from Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) for Ultomiris ravulizumab-cwvz to block complement-mediated thrombotic microangiopathy in patients with atypical hemolytic uremic syndrome....
09:01 , Jun 19, 2019 |  BC Extra  |  Financial News

Coenzyme A company Comet debuts with $28.5M series A

Led by former Syntimmune CEO David de Graaf, Comet launched Wednesday with $28.5 million in series A funding to develop precursors of coenzyme A to treat metabolic, immune and neurological disorders that involve dysregulated coenzyme...
22:28 , Jun 18, 2019 |  BC Extra  |  Company News

Japanese approvals include a global first for Roche's tissue-agnostic cancer drug

Among the four Japanese drug approvals announced on Tuesday was the global first for tissue-agnostic cancer therapy Rozlytrek entrectinib from Roche. Japan's Ministry of Health, Labour and Welfare (MHLW) approved the inhibitor of ROS1, TrkA,...
19:11 , May 31, 2019 |  BC Extra  |  Company News

Vigeo debuts to reprogram tumor microenvironment

Vigeo emerged from stealth Friday with $27.5 million from Morningside Venture Capital and a cancer candidate already in the clinic. Vigeo Therapeutics Inc. (Cambridge, Mass.) is developing a pipeline of peptides, fusion proteins and antibodies...
18:43 , May 22, 2019 |  BC Extra  |  Company News

AlloVir, first to test ElevateBio's model, raises $120M ahead of Phase III

The first disclosed company that will test newly launched ElevateBio's cell and gene therapy model is antiviral treatment developer AlloVir, which revealed the companies' relationship along with a $120 million series B round on Wednesday....